Warning letter
Homeocare Laboratories, Inc.: warning letter of Sep 7, 2017
FDA warning letter 521717 · New Jersey District Office
Key facts
| Reference number | 521717 |
|---|---|
| Company | Homeocare Laboratories, Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated/Misbranded |
| Issue date | Sep 7, 2017 |
| Posted date | Sep 12, 2017 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| CFR sections cited | 211.100(a), 201.5, 211.34, 211.84(d)(1), 211.110(a), 211.180(e) |
| Inspection city | Yonkers |
| Inspection ZIP | 10701 |
| Inspection start date | Jan 4, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: